Engineering a synthetic niche for hADSC preconditioning with PRP, Lp-SN, and resveratrol nanoparticles.
Abbasi S., Akbari N., Yazdani M., Dianat-Moghadam H., Khalili M.
Laboratory Study, published in Artif Cells Nanomed Biotechnol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Artif Cells Nanomed Biotechnol (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42360319
- DOI
- 10.1080/21691401.2026.2691659
Abstract (original English)
Ex vivo expansion of human adipose-derived stem cells (hADSCs) remains challenging because reduced-serum culture conditions can compromise short-term cell function. Here, we evaluated a microenvironment-inspired tri-component preconditioning regimen composed of platelet-rich plasma (PRP), Lactobacillus plantarum cell-free supernatant (Lp-SN), and resveratrol-loaded PLGA nanoparticles (RSV-PLGA-NPs) as a reduced-serum culture support strategy. Using a Box-Behnken design, we identified a formulation space in which PRP, Lp-SN, and RSV-PLGA-NPs were associated with improved hADSC viability and increased expression of selected stemness-associated genes in vitro. Omission-control experiments comparing the full formulation with partial combinations and blank PLGA NPs showed attenuated responses when individual components were removed, whereas the NP carrier alone had no significant effect. These findings support the utility of this tri-component system as a preliminary ex vivo preconditioning approach for short-term hADSC culture support. However, the results should be interpreted within the limits of the present in vitro study, as long-term expansion, post-treatment differentiation capacity, and in vivo performance were not evaluated.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.